A model approach to biologics. Premera's method of analyzing the potential benefits of Byetta shows how third-party modeling can pinpoint which members can benefit from easier access--and how plans can determine authentic cost savings.
Carroll
John
J
D001688:Biological Products / Q000191:economics / Q000627:therapeutic use*; D017046:Cost Savings; D003657:Decision Making; D006297:Health Services Accessibility; D006801:Humans; D007349:Insurance, Health, Reimbursement; D008962:Models, Theoretical; D019982:Organizational Case Studies; D014481:United States
D001688:Biological Products